Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy: Report from the registry data in Japan

Journal of Cardiology

Volumn 61, Issue 1, 2013, Pages 65-70

  Goto, Daisuke ^a   Kinugawa, Shintaro ^a   Hamaguchi, Sanae ^a   Sakakibara, Mamoru ^a   Tsuchihashi Makaya, Miyuki ^b   Yokota, Takashi ^a   Yamada, Satoshi ^a   Yokoshiki, Hisashi ^a   Tsutsui, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Dilated cardiomyopathy; Heart failure; Hypertrophic cardiomyopathy; Prognosis

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE; WARFARIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DILATED HYPERTROPHIC CARDIOMYOPATHY; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; JAPAN; MALE; SEX DIFFERENCE; SUDDEN DEATH;

AGED; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK;

EID: 84872392985     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.08.010     Document Type: Article

References (31)

1. ten Cate F.J., Roelandt J. Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy. Am Heart J 1979, 97:762-765.
2. Beder S.D., Gutgesell H.P., Mullins C.E., McNamara D.G. Progression from hypertrophic obstructive cardiomyopathy to congestive cardiomyopathy in a child. Am Heart J 1982, 104:155-156.
3. Funakoshi M., Imamura M., Sasaki J., Fujino M., Kawano T., Sasaki Y., Nakashima Y., Motooka T., Fukuda K., Imagawa M. Seventeen year follow-up of a patient with hypertrophic cardiomyopathy which progressed to dilated cardiomyopathy. Jpn Heart J 1984, 25:805-809.
4. Yutani C., Imakita M., Ishibashi-Ueda H., Hatanaka K., Nagata S., Sakakibara H., Nimura Y. Three autopsy cases of progression to left ventricular dilatation in patients with hypertrophic cardiomyopathy. Am Heart J 1985, 109:545-553.
5. Hecht G.M., Klues H.G., Roberts W.C., Maron B.J. Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. J Am Coll Cardiol 1993, 22:489-497.
6. Bingisser R., Candinas R., Schneider J., Hess O.M. Risk factors for systolic dysfunction and ventricular dilatation in hypertrophic cardiomyopathy. Int J Cardiol 1994, 44:225-233.
7. Seiler C., Jenni R., Vassalli G., Turina M., Hess O.M. Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy. Br Heart J 1995, 74:508-516.
8. Kawano S., Iida K., Fujieda K., Yukisada K., Magdi E.S., Iwasaki Y., Tabei F., Yamaguchi I., Sugishita Y. Response to isoproterenol as a prognostic indicator of evolution from hypertrophic cardiomyopathy to a phase resembling dilated cardiomyopathy. J Am Coll Cardiol 1995, 25:687-692.
9. Thaman R., Gimeno J.R., Murphy R.T., Kubo T., Sachdev B., Mogensen J., Elliott P.M., McKenna W.J. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 2005, 91:920-925.
10. Biagini E., Coccolo F., Ferlito M., Perugini E., Rocchi G., Bacchi-Reggiani L., Lofiego C., Boriani G., Prandstraller D., Picchio F.M., Branzi A., Rapezzi C. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005, 46:1543-1550.
11. Harris K.M., Spirito P., Maron M.S., Zenovich A.G., Formisano F., Lesser J.R., Mackey-Bojack S., Manning W.J., Udelson J.E., Maron B.J. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006, 114:216-225.
12. Hamada T., Kubo T., Kitaoka H., Hirota T., Hoshikawa E., Hayato K., Shimizu Y., Okawa M., Yamasaki N., Matsumura Y., Yabe T., Takata J., Doi Y.L. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy. Clin Cardiol 2010, 33:E24-E28.
13. Tsutsui H., Tsuchihashi-Makaya M., Kinugawa S., Goto D., Takeshita A. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 2006, 70:1617-1623.
14. Tsuchihashi-Makaya M., Hamaguchi S., Kinugawa S., Yokota T., Goto D., Yokoshiki H., Kato N., Takeshita A., Tsutsui H. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs. preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009, 73:1893-1900.
15. Hamaguchi S., Yokoshiki H., Kinugawa S., Tsuchihashi-Makaya M., Yokota T., Takeshita A., Tsutsui H. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009, 73:2084-2090.
16. Hamaguchi S., Kinugawa S., Tsuchihashi-Makaya M., Goto K., Goto D., Yokota T., Yamada S., Yokoshiki H., Takeshita A., Tsutsui H. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J 2010, 160:1156-1162.
17. Hamaguchi S., Furumoto T., Tsuchihashi-Makaya M., Goto K., Goto D., Yokota T., Kinugawa S., Yokoshiki H., Takeshita A., Tsutsui H. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 2011, 151:143-147.
18. Tsuchihashi-Makaya M., Hamaguchi S., Kinugawa S., Goto K., Goto D., Furumoto T., Yamada S., Yokoshiki H., Takeshita A., Tsutsui H. Sex differences with respect to clinical characteristics, treatment, and long-term outcomes in patients with heart failure. Int J Cardiol 2011, 150:338-339.
19. Klues H.G., Schiffers A., Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995, 26:1699-1708.
20. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287:1308-1320.
21. Dec G.W., Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994, 331:1564-1575.
22. Melacini P., Basso C., Angelini A., Calore C., Bobbo F., Tokajuk B., Bellini N., Smaniotto G., Zucchetto M., Iliceto S., Thiene G., Maron B.J. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J 2010, 31:2111-2123.
23. Shigematsu Y., Hamada M., Nagai T., Nishimura K., Inoue K., Suzuki J., Ogimoto A., Higaki J. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol 2011, 58:18-25.
24. Olivotto I., Cecchi F., Casey S.A., Dolara A., Traverse J.H., Maron B.J. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001, 104:2517-2524.
25. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Stromberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
26. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., Oates J.A., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
27. Maron B.J., Shen W.K., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., Bardy G.H., Favale S., Rea R.F., Boriani G., Estes N.A., Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365-373.
28. Rogers D.P., Marazia S., Chow A.W., Lambiase P.D., Lowe M.D., Frenneaux M., McKenna W.J., Elliott P.M. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 2008, 10:507-513.
29. Waller T.A., Hiser W.L., Capehart J.E., Roberts W.C. Comparison of clinical and morphologic cardiac findings in patients having cardiac transplantation for ischemic cardiomyopathy, idiopathic dilated cardiomyopathy, and dilated hypertrophic cardiomyopathy. Am J Cardiol 1998, 81:884-894.
30. Kitaoka H., Kubo T., Okawa M., Takenaka N., Baba Y., Yamasaki N., Matsumura Y., Furuno T., Doi Y.L. Plasma metalloproteinase levels and left ventricular remodeling in hypertrophic cardiomyopathy in patients with an identical mutation. J Cardiol 2011, 58:261-265.
31. Kitaoka H., Kubo T., Baba Y., Yamasaki N., Matsumura Y., Furuno T., Doi Y.L. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J Cardiol 2012, 59:209-214.